A recent study suggests that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt traditional lifestyle plans.
Published data in a major medical journal demonstrates that while obese individuals can lose a large proportion of their total mass while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals using these medications need to be informed of the risk of fast rebound weight gain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment mass in about one and a half years.
Comparing Treatments
The study, which reviewed 37 of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with other pills.
Scientists note that individuals who lose weight through lifestyle changes alone generally see a slower weight regain—approximately 100 grams monthly—after stopping.
The Reason for the Fast Rebound
Nutrition scientists propose the way of the drugs is key to understanding the accelerated regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls hunger.
"Long-term administration of the hormone levels several times higher than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' means appetite is uncontrolled, making overeating a significant risk."
An Ongoing Condition?
Health authorities recommend the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, due to the likelihood of weight regain, the treatment is often long-term.
This view is supported by drug manufacturers, who state that the results "emphasize the chronic character of obesity," akin to managing diseases like hypertension.
User Accounts
Individuals who have come off the jabs describe a intense resurgence of hunger.
"It was like a trigger flipping and I was suddenly starving," described a patient.
This challenge is compounded if patients have not developed permanent lifestyle or habit changes during therapy.
Widespread Interest
Survey data indicate that a significant number of people in the UK have used these injections in the past year, with demand continuing to grow.
- Use is greater among women than males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
Finally, researchers emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic cure and long-term success relies on combined behavioural management.
